Last updated on April 24, 2014 at 6:16 EDT

New research points to benefits of innovative cobas® HPV test for primary screening as England’s cervical cancer screening programme includes the test in current HPV “triage” rollout

November 17, 2011

LONDON, November 17, 2011 /PRNewswire/ –

As the new cobas HPV test from Roche is accepted for the national
cervical cancer screening programme in England for use at triage, further
research also supports the use of Roche’s cobas HPV test in “primary”
screening as part of a more sensitive and more efficient strategy in the
fight against cervical cancer

Data from a sub-analysis of the ATHENA (Addressing THE Need for Advanced
HPV Diagnostics) landmark study, recently published online in The Lancet
Oncology, demonstrated that the Roche cobas HPV Test, could be used for the
primary screening of cervical cancer. The data also showed that identifying
women with HPV 16 and/or 18, the two genotypes detected in approximately 70
per cent of cervical cancers, provided important predictive information to
determine a woman’s risk of cervical disease.

Current guidelines for cervical cancer screening allow for cytology
testing (Pap test) to determine the risk of cervical cancer. However, data
demonstrated that HPV DNA testing as primary (first-line) screening
identified cervical disease at a higher rate than cytology alone. These
results indicate that HPV testing for pooled high risk HPV with simultaneous
HPV 16 and HPV 18 genotyping, could provide a more sensitive and more
efficient strategy for cervical cancer screening. “The ATHENA study
continues to provide ample data to help refine and advance HPV screening,”
said Mark H. Stoler, MD, Professor and Associate Director of Surgical
Pathology and Cytopathology at the University of Virginia Health System.
“These new data suggest that HPV testing is an efficient, reliable and
potentially cost-effective primary screening tool. Moreover, the use of the
HPV 16 and 18 genotyping information provided by the cobas(R) HPV Test or
reflex cytology, would offer a rational approach for determining which HPV
positive women need immediate follow up.”

The cobas HPV Test is the only FDA and CE-IVD approved screening test
available in the UK and globally, that individually identifies genotypes 16
and 18, while simultaneously detecting 12 other high-risk HPV genotypes. For
laboratory professionals, the test also offers maximum ease of use,
reliability and flexibility.

In a separate study published online by the Journal of Clinical
Microbiology, a team of Dutch HPV experts led by Danielle Heideman, PhD,
clinically validated the cobas 4800 System and the cobas HPV Test for use in
primary screening for cervical cancer. The Netherlands was one of the first
European nations to announce its intention to use HPV testing as a primary
screen for cervical cancer.

Paul Eros, Director of Molecular Diagnostics at Roche in the UK said
“Women across England who have abnormal or borderline cervical screen test
results will now benefit from an innovation like the cobas HPV Test which
improves diagnosis of cervical pre-cancer. It is also particularly
encouraging to see the results of the ATHENA sub-analysis and the Dutch
study which demonstrate the validity of the cobas(R) HPV Test for primary
screening.” Introducing HPV testing at the primary screening stage in
England and all parts of the UK would provide an even earlier opportunity to
identify women at most risk of cervical cancer before the disease has

About the Roche ATHENA Clinical Trial

The Roche ATHENA study for the cobas HPV Test is the largest U.S.-based
registration study for cervical cancer screening, including more than 47,000
women. The study is designed to answer current medical and scientific
questions about the importance of testing for high-risk HPV genotypes in
cervical cancer screening and to provide clinical information about the
specific HPV genotypes that place women at highest risk for developing
cervical cancer. Results show the cobas HPV Test is comparable to the
current standard of testing. Results also demonstrated that one in 10 women,
age 30-years and older, who tested positive for HPV 16 and/or 18 by the
cobas HPV Test had cervical pre-cancer, although their Pap test was normal.

About the cobas HPV Test on the cobas 4800 platform

Roche’s cobas HPV Test simultaneously detects 12 high-risk HPV types
(HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) as a pooled
result, as well as HPV genotypes 16 and 18 individually. Roche received FDA
approval on the cobas HPV Test and in April 2011 and launched the cobas HPV
Test in countries that accept CE Mark in 2009.

Due to key features such as the “load and go” facility for reagents, The
cobas HPV test is easy and simple to use with minimal hands-on and maximum
walkaway time whilst providing high throughput capabilities and has the
flexibility to meet smaller throughput requirements.

About Human Papillomavirus and Cervical Cancer

Persistent infection with human papillomavirus is the cause of cervical
cancer in women, with HPV being found in 99.7 per cent of cervical cancers
worldwide. Of the more than 118 different types of HPV, the cobas(R) HPV
Test identifies the 14 high-risk types associated with the development of
cervical cancer and its precursor lesions. HPV types 16 and 18 have been
identified as the highest risk genotypes, detected in approximately 70 per
cent of cervical cancers. Nucleic acid (DNA) testing is a sensitive and
non-invasive method for determining the presence of HPV infection.

The World Health Organization estimates there are 470,000 new cases of
cervical cancer annually.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in
research-focused healthcare with combined strengths in pharmaceuticals and
diagnostics. Roche is the world’s largest biotech company with truly
differentiated medicines in oncology, virology, inflammation, metabolism and
CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based
cancer diagnostics and a pioneer in diabetes management. Roche’s
personalised healthcare strategy aims at providing medicines and diagnostic
tools that enable tangible improvements in the health, quality of life and
survival of patients. In 2010, Roche had over 80,000 employees worldwide and
invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5
billion Swiss francs. Genentech, United States, is a wholly owned member of
the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
For more information: http://www.roche.com and


All trademarks used or mentioned in this release are protected


Source: PR Newswire